186 related articles for article (PubMed ID: 10653662)
21. Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2.
Mores A; Matziari M; Beau F; Cuniasse P; Yiotakis A; Dive V
J Med Chem; 2008 Apr; 51(7):2216-26. PubMed ID: 18324760
[TBL] [Abstract][Full Text] [Related]
22. Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1.
Wilding B; Pasqua AE; E A Chessum N; Pierrat OA; Hahner T; Tomlin K; Shehu E; Burke R; Richards GM; Whitton B; Arwert EN; Thapaliya A; Salimraj R; van Montfort R; Skawinska A; Hayes A; Raynaud F; Chopra R; Jones K; Newton G; Cheeseman MD
Bioorg Med Chem Lett; 2021 Jun; 42():128050. PubMed ID: 33887439
[TBL] [Abstract][Full Text] [Related]
23. Phosphinic peptides, the first potent inhibitors of astacin, behave as extremely slow-binding inhibitors.
Yiallouros I; Vassiliou S; Yiotakis A; Zwilling R; Stöcker W; Dive V
Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):375-9. PubMed ID: 9531473
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel non-competitive inhibitors of mammalian neutral M1 aminopeptidase (APN).
Pascual I; Valiente PA; García G; Valdés-Tresanco ME; Arrebola Y; Díaz L; Bounaadja L; Uribe RM; Pacheco MC; Florent I; Charli JL
Biochimie; 2017 Nov; 142():216-225. PubMed ID: 28964831
[TBL] [Abstract][Full Text] [Related]
25. [Identification of metabolic pathways of brain angiotensin II and angiotensin III: predominant role of angiotensin III in the control of vasopressin secretion].
Llorens-Cortes C
C R Seances Soc Biol Fil; 1998; 192(4):607-18. PubMed ID: 9842467
[TBL] [Abstract][Full Text] [Related]
26. 3-Amino-2-tetralone derivatives: novel potent and selective inhibitors of aminopeptidase-M (EC 3.4.11.2).
Schalk C; d'Orchymont H; Jauch MF; Tarnus C
Arch Biochem Biophys; 1994 May; 311(1):42-6. PubMed ID: 7910449
[TBL] [Abstract][Full Text] [Related]
27. Aminopeptidase A inhibitors as potential central antihypertensive agents.
Reaux A; Fournie-Zaluski MC; David C; Zini S; Roques BP; Corvol P; Llorens-Cortes C
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13415-20. PubMed ID: 10557335
[TBL] [Abstract][Full Text] [Related]
28. Cell surface aminopeptidase A and N activities in human glomerular epithelial cells.
Stefanovic V; Vlahovic P; Ardaillou N; Ronco P; Ardaillou R
Kidney Int; 1992 Jun; 41(6):1571-80. PubMed ID: 1354270
[TBL] [Abstract][Full Text] [Related]
29. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
30. Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P.
Hooper NM; Hryszko J; Oppong SY; Turner AJ
Hypertension; 1992 Mar; 19(3):281-5. PubMed ID: 1312513
[TBL] [Abstract][Full Text] [Related]
31. Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs.
Chen H; Noble F; Roques BP; Fournié-Zaluski MC
J Med Chem; 2001 Oct; 44(21):3523-30. PubMed ID: 11585456
[TBL] [Abstract][Full Text] [Related]
32. Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A.
Vazeux G; Wang J; Corvol P; Llorens-Cortès C
J Biol Chem; 1996 Apr; 271(15):9069-74. PubMed ID: 8621556
[TBL] [Abstract][Full Text] [Related]
33. A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors.
Gao J; Marc Y; Iturrioz X; Leroux V; Balavoine F; Llorens-Cortes C
Clin Sci (Lond); 2014 Aug; 127(3):135-48. PubMed ID: 24697296
[TBL] [Abstract][Full Text] [Related]
34. Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor.
Chen H; Roques BP; Fournié-Zaluski MC
Bioorg Med Chem Lett; 1999 Jun; 9(11):1511-6. PubMed ID: 10386926
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements.
Harbeson SL; Rich DH
J Med Chem; 1989 Jun; 32(6):1378-92. PubMed ID: 2566685
[TBL] [Abstract][Full Text] [Related]
36. A stereoselective synthesis of phosphinic acid phosphapeptides corresponding to glutamyl-gamma-glutamate and incorporation into potent inhibitors of folylpoly-gamma-glutamyl synthetase.
Bartley DM; Coward JK
J Org Chem; 2005 Aug; 70(17):6757-74. PubMed ID: 16095295
[TBL] [Abstract][Full Text] [Related]
37. First synthesis of alpha-aminoalkyl-(N-substituted)thiocarbamoyl-phosphinates: inhibitors of aminopeptidase N (APN/CD13) with the new zinc-binding group.
Grzywa R; Oleksyszyn J
Bioorg Med Chem Lett; 2008 Jul; 18(13):3734-6. PubMed ID: 18524593
[TBL] [Abstract][Full Text] [Related]
38. Progress in the development of aminopeptidase N (APN/CD13) inhibitors.
Xu W; Li Q
Curr Med Chem Anticancer Agents; 2005 May; 5(3):281-301. PubMed ID: 15992355
[TBL] [Abstract][Full Text] [Related]
39. Development of selective inhibitors and substrate of matrix metalloproteinase-12.
Devel L; Rogakos V; David A; Makaritis A; Beau F; Cuniasse P; Yiotakis A; Dive V
J Biol Chem; 2006 Apr; 281(16):11152-60. PubMed ID: 16481329
[TBL] [Abstract][Full Text] [Related]
40. The C-terminal domain of aminopeptidase A is an intramolecular chaperone required for the correct folding, cell surface expression, and activity of this monozinc aminopeptidase.
Rozenfeld R; Muller L; El Messari S; Llorens-Cortes C
J Biol Chem; 2004 Oct; 279(41):43285-95. PubMed ID: 15263000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
